Head to Head Review: Personalis (NASDAQ:PSNL) and Bruker (NASDAQ:BRKR)

Bruker (NASDAQ:BRKR) and Personalis (NASDAQ:PSNL) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation and risk.

Valuation and Earnings

This table compares Bruker and Personalis”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bruker	$3.44 billion	2.51	-$8.60 million	($0.70)	-80.77
Personalis	$69.67 million	23.94	-$81.27 million	($1.09)	-14.61

Bruker has higher revenue and earnings than Personalis. Bruker is trading at a lower price-to-earnings ratio than Personalis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Bruker and Personalis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bruker	-2.35%	12.47%	4.91%
Personalis	-153.84%	-46.47%	-35.30%

Risk and Volatility

Bruker has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500. Comparatively, Personalis has a beta of 2.32, suggesting that its stock price is 132% more volatile than the S&P 500.

Institutional & Insider Ownership

79.5% of Bruker shares are owned by institutional investors. Comparatively, 61.9% of Personalis shares are owned by institutional investors. 27.2% of Bruker shares are owned by insiders. Comparatively, 4.2% of Personalis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations and price targets for Bruker and Personalis, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bruker	1	6	5	2	2.57
Personalis	1	7	3	0	2.18

Bruker presently has a consensus price target of $59.43, suggesting a potential upside of 5.11%. Personalis has a consensus price target of $14.54, suggesting a potential downside of 8.75%. Given Bruker’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Bruker is more favorable than Personalis.

Summary

Bruker beats Personalis on 12 of the 15 factors compared between the two stocks.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.

About Personalis

Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.